Lead Program (unspecified)

About Wincal BioPharm

Wincal Biopharm is a private, preclinical-stage biotech company developing innovative ocular therapeutics. Its core assets are a proprietary Ocular Penetration Carrier (OPC) platform designed to enable topical eyedrop delivery of large-molecule drugs to the back of the eye, and a pipeline of next-generation anti-VEGF and tri-specific antibodies. The company aims to replace invasive intravitreal injections, with a lead program targeting a clinical trial initiation in 2027. Wincal is positioned in the large and growing market for retinal disease treatments, but faces significant technical and competitive risks inherent to novel drug delivery and development.

About BlueHaven Therapeutics

Blue Wave Therapeutics is a Munich-based, private biotech company founded in 2020, operating in the rapidly growing radiopharmaceuticals sector. It is developing a novel platform using targeted alginate nanoparticles to deliver radionuclides like Actinium-225 for the precise treatment of solid tumors, starting with glioblastoma. The company is in the preclinical stage, actively seeking a CHF 3.5M+ seed round to advance its lead program and expand its pipeline. Its experienced team has backgrounds in radiopharmaceuticals, oncology development, and significant capital raising.

About Veraxa Biotech

Veraxa Biotech is a private, preclinical-stage biotech company developing next-generation antibody-based cancer therapeutics. Its core technology platform includes proprietary BiTAC (bispecific T cell engager) and advanced ADC (antibody-drug conjugate) technologies, aimed at creating safer and more effective treatments. Founded on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL), the company is led by an experienced management team with backgrounds in drug development, venture capital, and major biopharma firms like Amgen and Harpoon Therapeutics. Veraxa is advancing a pipeline of novel candidates, with its lead program in clinical studies for AML.

About Opsidio

Opsidio is an early-stage biotech targeting chronic inflammatory diseases, with an initial clinical program in moderate-to-severe atopic dermatitis already in Phase 2. The company operates in the competitive but high-value antibodies and biologics sector, aiming to address unmet needs in fibrosis and other inflammation-mediated conditions. As a private, pre-revenue company, its near-term success hinges on clinical data readouts and securing further funding to advance its pipeline. Its strategic focus on a validated biological pathway with a novel therapeutic approach positions it in a significant market opportunity.

Therapeutic Areas